AstraZeneca’s (NYSE:AZN) rare disease division, Alexion, announced that its experimental treatment anselamimab did not ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Sanofi has been granted a speedy review from the FDA for a gene therapy for geographic atrophy (GA), a complication of age-related macular degeneration (AMD), as it prepares to test it in a clinical ...

US pharma major AstraZeneca today released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) ...

Donald Trump has threatened new tariffs on medicines within weeks as he steps up demands for drugmakers to move factories to ...

An antibody being developed by AstraZeneca for the treatment of light chain (AL) amyloidosis has failed to move the needle in ...

Britain launched a life sciences sector plan on Wednesday to a mixed response from the pharmaceutical industry, which welcomed proposals to boost R&D but warned it would fail to keep firms competitive ...

Baxdrostat meets primary and all secondary endpoints in BaxHTN phase III trial in patients with uncontrolled or treatment resistant hypertension: Cambridge, UK Wednesday, July 16, ...

London's main stock indexes were subdued on Wednesday, as a stronger-than-expected rise in domestic inflation slightly cooled bets of interest rate cuts from the Bank of England.

An experimental AstraZeneca (NASDAQ:AZN) drug, anselamimab, failed to extend survival or cut heart-related hospitalizations in patients with a rare plasma cell disorder, disappointing hopes it could ...

Investing.com -- AstraZeneca’s (ST: AZN) rare disease unit Alexion (NASDAQ: ALXN) said its experimental drug anselamimab ...

AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. | ...